Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial) (LUTEAL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02625532 |
Recruitment Status : Unknown
Verified August 2018 by Joaquín Llácer, Instituto Bernabeu.
Recruitment status was: Active, not recruiting
First Posted : December 9, 2015
Last Update Posted : August 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Reproductive Techniques, Assisted | Procedure: Follicular phase Procedure: Luteal phase | Not Applicable |
Two arms is established, the study group that will start ovarian stimulation in the luteal phase and the control group that will start ovarian stimulation in the follicular phase.
The randomization will be made in the 2-3 day of the menstrual cycle, according to a list of random allocation of treatments. After check that there is no contraindication to start the stimulation, the patients will be assigned to the treatment group.
The patients in the control group (follicular phase group) will start stimulation with two vials of 150 IU recombinant FSH + 75 IU recombinant LH (Pergoveris® 150/75). The patients in the study group (luteal phase group) will perform daily urine LH test from day 7th of the cycle and will start the administration of 150 IU recombinant FSH + 75 IU recombinant LH (Pergoveris® 150/75) at two vials daily from the 4th day of the LH positive test.
Antagonist cetrorelix acetate (Cetrotide® ) administration will start when the largest follicle shall be equal or greater than 14 mm. From this moment controls every 24-72 hours with foliculometría by ultrasound and blood hormone analysis with determination of estradiol and progesterone. For the final oocyte maturation 2 vials daily of 0.2 mg triptorelin acetate (Decapeptyl®) is administered. Oocyte collection will be made by transvaginal ultrasound-guided puncture according to IB protocol
The dosages and protocols used will be the usual for patients with diagnostic of poor ovarian response.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles: A Randomized Comparative Single Center Trial. LUTEAL Trial |
Actual Study Start Date : | December 2015 |
Estimated Primary Completion Date : | October 2018 |
Estimated Study Completion Date : | January 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Follicular phase
Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
|
Procedure: Follicular phase
Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
Other Name: Ovarian stimulation starts during the follicular phase |
Experimental: Luteal phase
Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
|
Procedure: Luteal phase
Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
Other Name: Ovarian stimulation starts during the luteal phase |
- number of oocytes in metaphase II obtained [ Time Frame: Through study completion, average 2 weeks ]number of oocytes in metaphase II obtained by follicular puncture
- number of oocytes cumulus complexes [ Time Frame: Through study completion, average 2 weeks ]number of oocytes cumulus complexes obtained by follicular puncture
- duration of stimulation (days) [ Time Frame: Through study completion, average 2 weeks ]number of days from the start of ovarian stimulation until the day of follicular puncture
- cycle cancellation rate [ Time Frame: Through study completion, average 2 weeks ]ratio of canceled cycles regarding the number of ovarian stimulation cycles initiated
- Luteinizing hormone levels following administration of agonist for final oocyte maturation [ Time Frame: Through study completion, average 2 weeks ]Luteinizing hormone blood levels the day after administration of agonist for final oocyte maturation
- occurrence of side effects [ Time Frame: Through study completion, average 2 weeks ]occurrence of side effects at the end of study
- fertilization rate [ Time Frame: Through study completion, average 2 weeks ]Number of correct fertilization oocytes 18 hours post-insemination

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patient Bologna meets the criteria to be diagnosed as low responder
- Age under 41 years
- Regular menstrual cycles between 21 and 35 days
- Indication of in vitro fertilization
- Indication of start stimulation with 300 IU of FSH
- Presence of both ovaries
- Ability to participate and comply with the study protocol
- Having signed the written consent form
Exclusion Criteria:
- Presence of follicles larger than 10 mm in the randomization visit
- Endometriosis III / IV
- Concomitant uterine pathology: adenomyosis, submucosal myomas, Asherman's syndrome...
- Concurrent participation in another study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625532
Spain | |
Instituto Bernabeu | |
Alicante, Spain, 03016 |
Principal Investigator: | Joaquín Llácer | Instituto Bernabeu |
Responsible Party: | Joaquín Llácer, Gynaecologist. Reproductive Medicine Specialist at Instituto Bernabeu, Instituto Bernabeu |
ClinicalTrials.gov Identifier: | NCT02625532 |
Other Study ID Numbers: |
BER-LUT-2015-02 2015-003856-31 ( EudraCT Number ) |
First Posted: | December 9, 2015 Key Record Dates |
Last Update Posted: | August 29, 2018 |
Last Verified: | August 2018 |
Controlled Ovarian stimulation Follicular phase Luteal phase Reproductive Techniques, Assisted |